W J Valentine
Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK
Valentine W, Curtis B, Pollock R, Van Brunt K, Paczkowski R, Brändle M, Boye K, Kendall D. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. Diabetes Res Clin Pract 2015; 109:95-103.
21.04.2015Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK
21.04.2015Diabetes Res Clin Pract 2015; 109:95-103
Valentine W J, Curtis B H, Pollock R F, Van Brunt K, Paczkowski R, Brändle Michael, Boye K S, Kendall D M
Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
Brändle M, Erny-Albrecht K, Goodall G, Spinas G, Streit P, Valentine W. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. International journal of clinical pharmacology and therapeutics 2009; 47:501-15.
01.08.2009Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
01.08.2009International journal of clinical pharmacology and therapeutics 2009; 47:501-15
Brändle Michael, Erny-Albrecht K M, Goodall G, Spinas G A, Streit P, Valentine W J
Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting
Brändle M, Goodall G, Erny-Albrecht K, Erdmann E, Valentine W. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2009; 139:173-84.
21.03.2009Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting
21.03.2009Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2009; 139:173-84
Brändle Michael, Goodall G, Erny-Albrecht K M, Erdmann E, Valentine W J
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK
Valentine W, Massi-Benedetti M, Tan M, Yates J, Dormandy J, Williams R, Foos V, Brändle M, Palmer A, Bottomley J, PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabetic medicine : a journal of the British Diabetic Association 2007; 24:982-1002.
01.09.2007PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK
01.09.2007Diabetic medicine : a journal of the British Diabetic Association 2007; 24:982-1002
Valentine W J, Massi-Benedetti M, Tan M H, Yates J, Dormandy J A, Williams R, Foos V, Brändle Michael, Palmer A J, Bottomley J M, PROactive Study Group